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Abstract
Background: Primary hyperparathyroidism (PHPT) is an endocrine disorder most commonly affecting women, suggesting a
role for female hormones and/or their receptors in parathyroid adenomas. We here investigated the prolactin receptor
(PRLr) which is associated with tumours of the breast and other organs.
Methodology/Principal Findings: PRLr expression was investigated in a panel of 37 patients with sporadic parathyroid
tumours and its functionality in cultured parathyroid tumour cells. In comparison with other tissues and breast cancer cells,
high levels of prolactin receptor gene (PRLR) transcripts were demonstrated in parathyroid tissues. PRLr products of 60/
70 kDa were highly expressed in all parathyroid tumours. In addition varying levels of the 80 kDa PRLr isoform, with known
proliferative activity, were demonstrated. In parathyroid tumours, PRLr immunoreactivity was observed in the cytoplasm (in
all cases, n=36), cytoplasmic granulae (n=16), the plasma membrane (n=12) or enlarged lysosomes (n=4). In normal
parathyroid rim (n=28), PRLr was uniformly expressed in the cytoplasm and granulae. In in vitro studies of short-term
cultured human parathyroid tumour cells, prolactin stimulation was associated with significant transcriptional changes in
JAK/STAT, RIG-I like receptor and type II interferon signalling pathways as documented by gene expression profiling.
Moreover, PRLR gene expression in parathyroid tumours was inversely correlated with the patients’ plasma calcium levels.
Conclusions: We demonstrate that the prolactin receptor is highly abundant in human parathyroid tissues and that PRLr
isoforms expression and PRLr subcellular localisation are altered in parathyroid tumours. Responsiveness of PRLr to
physiological levels of prolactin was observed in the form of increased PTH secretion and altered gene transcription with
significant increase of RIG-I like receptor, JAK-STAT and Type II interferon signalling pathways. These data suggest a role of
the prolactin receptor in parathyroid adenomas.
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Introduction
Primary hyperparathyroidism (PHPT) is a common endocrine
disorder characterized by increased levels of serum calcium and
parathyroid hormone (PTH) and symptoms of e.g. osteoporosis,
kidney stones, psychological disturbances or cardiovascular disease
[1,2,3]. Available reports suggest that the disease affect approx-
imately 1% of the population. In addition, the incidence of PHPT
increases in women after menopause [4], where prevalence of 3%
have been reported [5]. The molecular background has been
elucidated for a large part of familial forms of the disease, caused
by constitutional mutations in the multiple endocrine neoplasia
type 1 gene (MEN1),the hyperparathyroidism-jaw tumour syn-
drome gene (HRPT2) or the calcium sensing receptor gene (CASR).
However, the molecular background remains unknown for the
majority of the common sporadic form of PHPT, caused by a
single benign parathyroid tumour. As this group most frequently
affects women it is suggested that female hormones and/or their
receptors may have a role in these tumours.
Human prolactin, a hormone secreted from the anterior
pituitary gland, is known to have multiple functions. In addition
to being responsible for lactation and mammary growth, prolactin
has calciotropic effects in the intestine, kidney and skeleton
[6,7,8,9] and has also been associated with cancer development e.g.
in the breast and ovary [10,11,12,13,14,15,16]. In pancreatic beta
cells, prolactin signalling is known to inhibit the MEN1 gene
product menin, causing b-cell proliferation during pregnancy
[17,18]. The prolactin receptor (PRLr), a type I cytokine receptor,
is encoded by the PRLR gene in chromosomal region 5p13.2. In
humans the five known functional isoforms are encoded by five
overlapping transcripts, produced by alternative splicing (Figure
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36448S1) [19]. While the long and DS1 PRLr isoforms, originally
isolated from T47D breast cancer cells, may activate proliferative
signalling through the Janus kinase/signal transducers and
activators of transcription (JAK/STAT) pathway, the short
isoforms IF, S1a and S1b lack the tyrosine rich residue required
for full STAT binding [20,21,22,23]. N-glycosylation of the
extracellular domain of PRLr is important for membrane
localization [24]. The protein kinase GSK3b is a key regulator
of PRLr degradation through phosphorylation of the PRLr serine
residue at amino acid position 349. In breast cancer cells,
inhibition of GSK3b through serine phosphorylation on residue
9 has been shown to correlate with elevated PRLr levels [25].
Some previous observations suggest a role for PRLr in
parathyroid cells. High PRLR expression in parathyroid adenomas
may be identified from previous reports of expression profiling of
parathyroid tissues reported by us and others [26,27], and from
expressed sequence tag (EST) profiling (Hs.368587) of parathyroid
adenoma (973 TPM) as compared to breast tumour (424 TPM)
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.
cgi?uglist=Hs.368587). In addition, PRLR knockout mice exhib-
ited phenotypic alterations of calcium, PTH levels and bone
formation [8,28]. Finally, prolactin stimulation of bovine parathy-
roid cells in vitro was reported to increase PTH secretion
independent of the parathyroid beta-adrenergic and dopaminergic
systems [29]. However, clinical observations of the relationship
between PTH and prolactin levels are conflicting, and processes in
vivo such as e.g. tumour induced hyperprolactinemia, pregnancy,
the menstrual cycle and polycystic ovary syndrome have proved
too complex to establish a consensus model of causality
[6,7,29,30,31,32,33,34,35,36,37,38,39].
Given the frequent occurrence of PHPT in women and the role
of PRLr in other tumours we aimed to assess PRLr expression and
functionality in human parathyroid tumours. We determined
PRLR gene and PRLr isoform expression in parathyroid tumours
and normal tissues, and evaluated parathyroid tumour cell
function and expression profiles upon prolactin stimulation in vitro.
Results
PRLR Gene Expression in Parathyroid Tissues
Expression of PRLR gene transcripts was determined by qRT-
PCR analyses of parathyroid tumours and normal tissues. Using
the PRLR-total assay (detecting LF, DS1, IF and S1a but not S1b),
the highest levels of expression was observed in parathyroid tissues
(Figure 1; Table S3). Non-parathyroid normal tissues had, as
expected, variable but lower expression than the MCF-7 cell line,
and the highest level of PRLR-total was observed in the placenta
(Figure S2). Normal parathyroid tissues expressed nearly tenfold
higher levels compared to the MCF-7 cell line. PRLR-total
expression was observed in 35/37 parathyroid tumours, at levels
that are higher (.1.5, n=7), lower (,0.5; n=9) or comparable
(.0.5 and ,1.5; n=19) to the mean level for the normal
parathyroids (0.77–1.30). Two additional assays were applied for
the detection of transcripts corresponding to LF and DS1, showing
that their expression levels generally followed the levels of PRLR-
total in parathyroid tissues (Figure S2A and S3). The PRLR-S1a
assay, detecting only the S1a transcript, showed that its level was
relatively low in MCF-7 (Figure S2B) and within the range of the
normal tissues (Figure S3).
Expression of the PRLR-DS1 transcript, or of all other PRLR
transcripts (except DS1), was demonstrated by regular qualitative
RT-PCR, using transcript specific primers and detection of
product of expected size by agarose gel electrophoresis. For
comparison expression of the other four transcripts PRLR-LF/IF/
S1a/S1b was similarly demonstrated by RT-PCR.
Expression of PRLr Isoforms and GSK3b in Parathyroid
Tumours
The PRLr was expressed in T47D breast cancer cells as an
80 kDa product, corresponding to the long isoform reported by
Galskaard et al. [40], while in normal parathyroid, breast and
fallopian tube a shorter PRLr product of 60–70 kDa was detected
(Figure 2). Nuclear extract of normal parathyroid tissue was
negative. PRLr expression was demonstrated by Western blot
analysis for both PRLr and the N-glycosylated form. The 60/
70 kDa PRLr product was expressed in all 37 parathyroid
tumours (Figure 2A; Table S3). In addition the 80 kDa isoform
was observed at levels similar to the 60/70 kD PRLr in 10
tumours or weaker in 15 tumours. In 12 tumours the 80 kDa
product was not revealed or barely detectable (Table S3). In the
normal parathyroid only the 60/70 kDa product was revealed. N-
glycosylated PRLr was mainly observed as a product of 60/
70 kDa in size, which was detected in all tumours analysed
(Figure 2A).
GSK3b is known to phosphorylate ser349 of the long and
DS1PRLr isoforms, and GSK3b ser9-phosphorylation is needed
for PRLr degradation [25]. We therefore analysed GSK3b
expression concerning levels of total GSK3b as well as the
serine-9 phosphorylated form (Figure 2B; Table S3). 35/37
parathyroid tumours and fallopian tube expressed total GSK3b
at comparable levels, while in 2 tumours only weak expression was
observed. Ser9-Phosphorylated GSK3b was strongly expressed in
29 parathyroid tumours (Figure 2B), weakly expressed in 6
tumours, and barely detectable in 2 (Table S3). Ser9-phosphor-
ylated GSK3b was not detected in the normal parathyroid gland.
As compared to the results for the 80 kDa PRLr product the 2
tumours with barely detectable Ser9-phosphorylated GSK3b
lacked the PRLr 80 kDa product (Table S3). Out of the 6
tumours with weak Ser9-phosphorylated GSK3b,3 lacked and one
had weak PRLr 80 kDa expression.
Expression and Subcellular Localization of PRLr in
Parathyroid Tumours
As different isoforms of the PRLr have been shown to be
differentially expressed and localized to diverse parts of the cell in
various tumours [41,42], we aimed to characterize the sub-cellular
localization as well as the overall expression of the PRLr using
immunohistochemistry. Overall, the immunohistochemical results
support our Western blot data suggesting that PRLr is expressed in
the vast majority of all parathyroid tumours investigated. Using
the PRLrI antibody, positive immunoreactivity was observed in all
tumours analysed (n=36), as well as in non-tumour parathyroid
cells located in the normal rim that was present in the majority of
parathyroid tumour sections (n=28). Analysis of the subcellular
localization revealed strong immunostaining in the cytoplasm and
cytoplasmic granulae of all normal rims. Nuclear staining was
never noted (Figure 3A). In contrast, several different staining
patterns were revealed in parathyroid tumours, as illustrated in
Fig. 3 and 4 (Table S3). Cytoplasmic expression of PRLr was
observed in virtually all tumour cells, in 34/36 analysed cases, and
16 tumours showed immunostaining of cytoplasmic granulae in
varying subsets of the cells. In addition, 12 tumours exhibited
plasma membrane staining. Generally, staining of plasma mem-
brane and granulae was not observed together in the same cell. In
4 cases staining of intracellular ‘‘ring-like’’ structures was observed
(Figure 4A). In order to identify the cytoplasmic location giving
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done in two such cases with parallel analysis of anti-PRLr and
markers for lysosomal or Golgi structures. In both cases, co-
localization was observed in the tumour tissue for anti-PRLr and
the lysosomal marker in the ‘‘ring-like’’ structures (Figure 4C), but
not for the Golgi marker (data not shown), suggesting that they
originate from PRLr localized to enlarged lysosomes. Further-
more, normal rim present in one of the cases showing PRLr
expression in the cytoplasm and granulae (Figure 4B) revealed co-
localization of anti-PRLr and the lysosomal marker in granulae
suggesting a lysosomal origin of the granulae structures
(Figure 4D).
A second antibody, PRLrA, was also evaluated by immunohis-
tochemistry on the same cases (exemplified in Figure S4). In all
normal rims analysed, immunoreactivity was observed in the
cytoplasm and/or plasma membrane at varying intensities and
proportions of the cells. Strong PRLr expression was detected in
24 tumours, while 5 had weak expression only and 7 were
negative. In the 29 positive tumours immunoreactivity was located
in both the cytoplasm and the plasma membrane (n=16), or in
either cytoplasm (n=12) or the plasma membrane (n=1). Focally
different expression patterns were noted in 8 cases, while
immunoreactivity was not evidently detected in nuclei, granulae
or lysosomes.
PRLR/PRLr Expression in Relation to Clinical
Characteristics of Tumour Patients
Comparison of the prolactin receptor gene expression with
clinical characteristics of the 37 parathyroid tumour cases revealed
several significant relationships. Inverse correlations were observed
between expression of PRLR and patients plasma calcium levels as
demonstrated using both the PRLR-total (r=20.333, P=0.044),
PRLR-LF1 (r=20.336, P=0.042) and the PRLR-LF2
(r=20.345, P=0.036) assays. The levels of PRLR-total were
significantly lower for patients with calcium levels within the
highest quartile (P=0.033) and similar tendencies were found for
PRLR-LF1, PRLR-LF2 and PRLR-S1a (P=0.068; P=0.061 and
P=0.053). With regard to the subcellular localization of PRLr,
membranous immunostaining was not observed in cases with
tumour weights in the highest quartile (P=0.045).
PTH Secretion and [Ca
2+]i at Prolactin Treatment of
Parathyroid Adenomas
A possible effect on PTH secretion from prolactin stimulation of
short-term cultured parathyroid tumour cells was studied by
parallel perifusion at two different prolactin concentrations (100 or
200 mg/L). The findings are presented in Figure 5A. In
summary, after 100 mg/L prolactin a 9.8613.2% increase
Figure 1. qRT-PCR analysis for PRLR expression in normal parathyroid tissue and parathyroid tumours. Box-plots showPRLR-total mRNA
expression after normalization in normal parathyroid tissue and parathyroid tumours (A), and normal parathyroid and other normal tissues (B). The
arbitrary value of 1.0 indicating the expression level in MCF-7 cells is indicated.
doi:10.1371/journal.pone.0036448.g001
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in PTH secretion at 9 min was observed. Although the observa-
tions did not reach statistical significance, each individual
experiment suggested an increase in PTH secretion. These
observations indicate that prolactin may stimulate PTH secretion
at a physiological concentration. Next, we investigated if [Ca
2+]i
signalling was involved in the regulation using the Ca
2+ indicator
Fura-2. As shown in Figure 5B, addition of 100 mg/L or 200 mg/L
prolactin did not significantly alter [Ca
2+]i levels.
Gene Expression Patterns upon Prolactin Stimulation
Comparative gene expression profiling was done using the
Affymetrix platform analysing parathyroid tumour cells treated
with 200 mg/L prolactin as compared to untreated controls.
After filtering of very low abundant probe sets, approximately
33,000 probe sets remained for further analysis. Paired t-test
between treated and untreated tumours identified 63 differen-
tially expressed probe sets (61 up-regulated and 2 down-
regulated, Table S2). Pathway analyses identified statistically
Figure 2. Western blot analysis of protein expression for GSK3b and isoforms of the prolactin receptor. A) Detection of 80 kDa and 60/
70 kDa products with the PRLrI antibody in normal tissues, T47D cells and parathyroid tumours, and 60/70 kDa N-glycosylated PRLr products with the
gPRLr antibody in parathyroid tumours. B) Expression of total GSK3b (left) as well as Ser9-phosphorylated GSK3b (right) in parathyroid tumours and
normal tissue.
doi:10.1371/journal.pone.0036448.g002
Prolactin Receptor in Primary Hyperparathyroidism
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e36448significant over-representation of dysregulated genes in the
signalling pathways for retinoic acid inducible gene-I (RIG-I)
like receptor-, JAK/STAT- and Type II interferon signalling
pathways (Table 1). In addition a Qlucore analysis was
performed. At PCA and clustering treated and control samples
separated into two groups (Figure 6). The heatmap shows 58
significantly differentially expressed genes, all of which were
upregulated. 44 of these genes overlapped with those detected
by paired t-test and fold change cut-off (Table S2).
Figure 3. Immunohistochemical analysis of PRLr expression using the PRLrI antibody. The photomicrographs show parathyroid tumour
tissues (A–C) and negative control (D). Parathyroid tumours are shown with immunostaining of cytoplasmic granulae and cytoplasm (A), of cytoplasm
only (B), and of cell membrane and cytoplasm (C).
doi:10.1371/journal.pone.0036448.g003
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In this study we demonstrate high abundance of the prolactin
receptor in parathyroid tissues, correlation of its expression levels
to clinical characteristics, as well as localization and functional
responses upon prolactin stimulation in parathyroid tumour cells.
Relatively high abundance of PRLr in parathyroid tissues was
demonstrated at the gene transcripts and protein isoforms levels.
The expression was compared with two cell lines frequently
used as models for PRLr signalling in breast cancer: T47D and
MCF-7 which are both known to express very high or high
PRLr levels, respectively [43]. In Western blot analyses of
parathyroid tissues, the 80 kDa PRLr product was detected at
levels comparable to the T47D cell line, which is known to
express the LF isoform [40]. Using qRT-PCR, parathyroid
tissues were shown to have considerably higher PRLR expression
compared to the MCF-7 cell line, which in turn had a higher
level than the non-parathyroid normal tissues. In non-parathy-
Figure 4. Localisation of PRLr expression to lysosomes in normal parathyroid rim and to enlarged lysosomes in parathyroid tumour
tissue. A) Immunohistochemistry with PRLrI showing ‘‘ring-like’’ cytoplasmic structures and cytoplasmic reactivity. B) Immunohistochemistry of PRLrI
showing cytoplasmic granuale and cytoplasmic reactivty. C and D) Analysis of ‘‘ring like’’ structures and cytoplasmic granulae by flourescent
immunohistochemistry. Images show one parathyroid tumour (C) and normal parathyroid rim (D), stained with DAPI (blue), anti-PRLrI (red, upper
right) and anti-SCARB2 (green lysosomal marker, lower left) separately and in overlay (lower right and upper left).
doi:10.1371/journal.pone.0036448.g004
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by kidney, pancreas and lung, and lowest in brain, heart, lung
and striated muscle, in agreement with previous observations by
Peirce and Chen [43]. The findings were also extended to the
analyses of individual transcripts, which showed similar results
as the PRLR-total assay for simultaneous detection of the LF,
DS1, IF and S1a transcripts. Hence the variation in PRLR
observed in parathyroid tumours was not evidently related to
the alteration of single transcripts.
GSK3b is able to phosphorylate ser349 of the prolactin receptor
[24], a residue existing only in the long and DS1 isoforms. PRLr
degradation is dictated by levels of GSK3b ser9-phosphorylation.
The latter is in turn a known downstream target of menin/AKT
signalling [44,45]. As menin is a known primary affected tumour
suppressor in parathyroid tumours, it is possible that its
dysfunction would cause a disinhibition of GSK3b mediated
degradation of PRLr, hence stabilizing the long/DS1 isoforms.
This could to some extent explain the variation of long isoform
Figure 5. Analysis of PTH secretion and intracellular Ca
2+ after prolactin treatment. A) Measurements of PTH secretion from parathyroid
adenoma cells upon treatments with prolactin at 100 mg/L or 200 mg/L. Results from four independent experiments are shown. B) Example of a
measurement of intracellular Ca
2+ in parathyroid adenoma cells treated with 100 mg/L followed by 200 mg/L prolactin, as indicated by vertical red
lines.
doi:10.1371/journal.pone.0036448.g005
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mechanism is present in breast cancer, it would be an attractive
target for treatment. Additionally, patients treated with lithium,
which most likely leads to GSK3b phosphorylation [44,46], are
known to be highly prone to parathyroid tumours [47,48,49]. This
connection remains to be investigated.
Comparison of parathyroid tumours and normal parathyroid
tissues did not reveal differential levels of expression that were
consistently reduced or increased as for a classical tumour
suppressor or oncogene mechanism. Instead, we observed both
increased and decreased levels of expression for total PRLR/PRLr
and the various transcripts and isoforms. Interestingly, a statisti-
cally significant inverse correlation was observed between the
PRLR gene expression and calcium levels, suggesting either a
relationship to a subgroup of tumours and/or a causal change of
calcium set point in the tumour.
PRLr expression showed frequent alteration of the subcellular
signal location as compared to normal parathyroid rim. The
PRLr expression pattern located to cytoplasm and granulae
uniformly observed in normal rim was partly changed in
parathyroid tumours. In the tumours the expression was
cytoplasmic with additional location in cell membrane, granulae
or enlarged lysosomes. Similar expression patterns with cyto-
plasmic granular and/or membranous location have been
reported for other tumour types, where PRLr expression has
also been associated with patient outcome [42]. In this study we
similarly observed associations to patient disease phenotypes,
both on protein and gene level. Specifically lack of membranous
immunoreactivity was associated with larger adenomas (forth
quartile). Still, in several parathyroid tumours membranous
immunostaining was not detected, raising the question whether
PRLr is still active in this subset of tumours. The association to
clinical characteristics in parathyroid and other tumours would
suggest a functional PRLr. Furthermore in vitro studies showed
effects on gene expression patterns in parathyroid tumours.
Taken together these results would suggest that PRLr is active
but that the membranous level is too low for detection or not
reachable by the antibody used in cases without strong
membranous signal.
Functional effects on hormone secretion were evaluated upon
prolactin stimulation of parathyroid adenoma cells. Although no
statistically significant effect was documented, the results suggested
that 200 mg/L PRL stimulate PTH-secretion in the acute phase in
agreement with previous observations by Magliola et al. in bovine
parathyroid cells [29]. However, in the bovine study prolactin
exposure was done at 0.1–1.0 mM, which would correspond to
supraphysiological levels. In healthy women prolactin levels are 7–
10 mg/L under normal conditions, and rise to 75–100 mg/L
Table 1. Pathways with enrichment of dysregulated genes.
Pathway Fold Gene Ensembl
Gene number change symbol Gene name gene ID
RIG-I-like receptor signaling (KEGG 04622)
(C=70; O=6; E=0.21; R=28.27; rawP=6.80e-08; adjP=1.36e-07)
23586 3.37 DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 ENSG00000107201
3665 3.14 IRF7 Interferon regulatory factor 7 ENSG00000185507
79132 2.19 DHX58 DEXH (Asp-Glu-X-His) box polypeptide 58 ENSG00000108771
64135 2.43 IFIH1 Interferon induced with helicase C domain 1 ENSG00000115267
7706 1.79 TRIM25 Tripartite motif-containing 25 ENSG00000121060
9636 2.54 ISG15 ISG15 ubiquitin-like modifier ENSG00000187608
Jak-STAT signaling (KEGG 04630)
(C=153; O=4; E=0.46; R=8.62; rawP=0.0012; adjP=0.0012)
1154 1.78 CISH Cytokine inducible SH2-containing protein ENSG00000114737
6773 1.49 STAT2 Signal transducer and activator of transcription 2, 113 kDa ENSG00000170581
6772 2.03 STAT1 Signal transducer and activator of transcription 1, 91 kDa ENSG00000115415
10379 2.07 IRF9 Interferon regulatory factor 9 ENSG00000213928
Type II interferon signaling (Wikipathways WP619)
(C=50; O=7; E=0.15; R=46.18; rawP=1.49e-10; adjP=1.49e-10)
5610 2.27 EIF2AK2 Eukaryotic translation initiation factor 2-alpha kinase 2 ENSG00000055332
4938 7.71 OAS1 2’,5’-oligoadenylate synthetase 1, 40/46 kDa ENSG00000089127
2537 3.45 IFI6 Interferon, alpha-inducible protein 6 ENSG00000126709
6773 1.49 STAT2 Signal transducer and activator of transcription 2, 113 kDa ENSG00000170581
9636 2.54 ISG15 ISG15 ubiquitin-like modifier ENSG00000187608
6772 2.03 STAT1 Signal transducer and activator of transcription 1, 91 kDa ENSG00000115415
10379 2.07 IRF9 Interferon regulatory factor 9 ENSG00000213928
C=Number of reference genes in the category; O=Number of genes in the gene set and also in the category.
E=Expected number in the category; R=Ratio of enrichment.
rawP=p-value from hypergeometric test; adjP=p-value adjusted by the multiple test adjustment.
doi:10.1371/journal.pone.0036448.t001
Prolactin Receptor in Primary Hyperparathyroidism
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e36448during pregnancy and to 200–800 mg/L during lactation [32].
The present study suggests that PTH secretion may be acutely
stimulated at physiological levels of prolactin. In respect to the
observed correlation between PRLR gene expression and patient
calcium levels, a study comparing responsiveness in high and low
calcium phenotypes would be of interest.
In cultured parathyroid tumour cells, gene expression alter-
ations upon prolactin stimulation affected RIG-I like receptor
signalling, JAK-STAT signalling and Type II interferon signalling
which were all increased. The JAK-STAT pathway is known to be
activated by PRLr signalling [20]. Since PRLr is a cytokine
receptor, the increase of Type II interferon signalling could be
explained simply by PRLr engagement, or downstream co-
activation of interferon-c signalling by JAK2 crosstalk. A crosstalk
between RIG-I like receptor signalling and PRLr signalling has
not been described, suggesting that the upregulation cannot be
explained by a direct crosstalk effect alone. However, given the
common function of infectious response, a connection between the
Figure 6. Clustering and PCA analysis of differentially expressed genes after prolactin treatment in parathyroid adenoma cells. A)
Heat map of hierarchical clustering show 58 changed genes (adjusted P,0.01) as detected by Qlucore analysis. B) PCA of the gene expression data in
a 2D graph, plotting individual primary cultures of parathyroid adenomas. Colours indicate either; green=control or red=prolactin treated. Numbers
indicate individual cases. For significant genes (adjusted P,0.01), samples were grouped according to treatment. Lines indicate the three closest
relationships to a sample.
doi:10.1371/journal.pone.0036448.g006
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regarding gene expression profiling and coupling to the PRLr in
parathyroid tumours is known to be present, a direct comparison
of our findings with independent observations could not be made.
Some similarities between the effects observed in this study and
published results in non-related tissues from knock-out mice do
exist [20], thus supporting some of our main findings, such as
JAK-STAT up-regulation upon prolactin stimulation. The addi-
tion of a non-parathyroid, prolactin-responsive control as a
comparison could make an interesting backdrop to a future
delineation of the PRLr receptor in human tumour systems.
The results obtained in this study suggest a functional role of
PRLr in the parathyroid gland, and imply that PTH secretion may
be stimulated acutely by prolactin. Further studies are required to
evaluate the response to prolactin at different physiological and
pathological states. Prolactin has been proposed to be the main
calciotropic hormone during pregnancy, and is increased during
lactation. In addition, high levels of prolactin may result from
pathological conditions such as e.g. pituitary hyperfunction,
polycystic ovary syndrome and iatrogenic hyperprolactinemia.
Although this study does not conclude whether a physiological
correlation exists or not, a response of PTH to physiological levels
of prolactin is suggested. The earlier controversies regarding
possible prolactin-PTH levels causality might be explained by the
different dietary conditions of the subjects. For example, in North
America and Europe PTH has been reported to decrease during
pregnancy, while in areas of low or deficient dietary calcium (e.g.
Brazil and Gambia), PTH was found to increase [30,31,50]. This
difference may be a consequence of altered calcium recruitment
from intestine to maternal bones. Increased risk of breast cancer
has been associated with both high levels of prolactin [51] and
PHPT [52]. Interestingly, an association between childbearing and
PHPT has also been identified [53]. A logic continuation of the
present study would be to evaluate a possible connection between
prolactin levels and PHPT development.
In conclusion, we demonstrate high abundance of the prolactin
receptor in the human parathyroid gland, aberrant subcellular
localisation in parathyroid tumours, and varying levels
of PRLr isoforms. Responsiveness to physiological levels
of prolactin was observed in the form of increased PTH secretion
within minutes of treatment, and altered gene transcription with
significant increase of the RIG-I like receptor, JAK-STAT and
Type II interferon signalling pathways. These data suggest a role
of the prolactin receptor in parathyroid adenomas.
Materials and Methods
Ethics Statement
All parathyroid tumour samples and normal parathyroid tissues
had been collected according to the established procedure at the
Karolinska University Hospital as approved by the local ethical
committee. Tissue samples were thus obtained with oral informed
consent and documented in the patient files.
Parathyroid Tumour Tissue Samples and Cell Cultures
Parathyroid tumours from 37 patients with PHPT and
uniglandular disease were included in the study. Fresh-frozen
tissue samples and sections from paraffin embedded tissue had
been collected via the tissue biobank at Karolinska University
Hospital. The panel of 37 cases was selected to represent the
spectra of PHPT patients operated in the hospital during one year
based on age at surgery (median 59 years; min-max 27–86),
gender (30 female, 7 male), histopathological diagnosis and
glandular weight (median 709 mg; min-max 230–13,500). Median
total plasma calcium was 2.60 mmol/L (min-max 2.50–3.22), and
median P-PTH was 145 ng/L (min-max 66–1,280). Tumours
were diagnosed as adenoma (n=33) or atypical adenoma (n=4) in
routine clinical histopathology according to WHO criteria
[54]. Parathyroid adenoma samples for culturing and functional
studies were obtained at surgery after informed consent. Up to one
third of the tumour was collected from each sample, while the
majority of the tissue was sent to routine histopathological
diagnostics. Fresh tissue samples were quickly transferred in cold
culturing media to the nearby laboratory, and then isolated and
cultured using previously described methods [55]. All experiments
were performed within 72 hours after isolation.
Normal Samples
Normal non-tumour tissue of breast and fallopian tube samples
from anonymized breast and ovarian cancer patients were fresh-
frozen post-operatively. Normal parathyroid glands from normo-
calcemic patients were collected from patients operated for thyroid
cancer with indication for parathyroid gland removal without re-
implantation. All normal samples were stored at 280uC and
verified by a histopathologist. Total protein extract and nuclear
protein fraction of normal parathyroid tissue was commercially
obtained (Cat. no. NB820-59245 and NBL1-26415; Novus
Biologicals, Cambridge, UK). The MTC panel I purchased from
Clontech (Cat. no. 636742, Clontech Mountain View, CA)
includes cDNAs representing various normal tissues (normal
brain, heart, kidney, liver, lung, pancreas, placenta and striated
muscle). Two human breast carcinoma cell lines were used:
Lysates of T47D were commercially obtained (Abcam, Cam-
bridge, UK, cat. no ab14899); (Cat. no ab14899, Abcam,
Cambridge, UK); and MCF-7 RNA extracts were kindly provided
by Dr. Johan Hartman, Karolinska University Hospital.
Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR)
RNA was extracted using a commercially available kit
(RiboPure TM Kit, Applied Biosystems, Carlsbad, CA), and
concentrations were determined by Nanodrop ND-1000 (Nano-
drop technology, Wilmington, DE). Quality was evaluated using
an Agilent 2100 Bioanalyser (Santa Clara, CA), which showed that
all included samples had a RIN value of .7.9. cDNA was
synthesized with the High Capacity cDNA Reverse Transcription
Kit (ABI) in 20 ml reactions with ,15 mg/ml RNA and inclusion of
RNAse inhibitor under recommended conditions (37uC for
30 min, 80uC for 30 min, final 4uC).
The PCR was run using 10 ml reaction mixtures per well in a
384-well plate and an ABI 7900HT Fast Real Time PCR System
(ABI, Carlsbad, CA). The wells were loaded with equivalent
amount of cDNA (1 or 2 ml of RT-PCR product or MTC panel I
cDNA), 5 ml of Taqman universal mastermix II (ABI, Carlsbad,
CA) and 0.5 ml of Taqman assay. Taqman assays from ABI were
used including: PRLR-total (Assay on Demand Hs00168739_m1*
detecting LF, DS1, IF and S1a), and PRLR-LF1 (detecting LF and
DS1), PRLR-LF2 (detecting LF and DS1) and PRLR-S1a (detecting
S1a) which were designed by ABI and bioinformatically analysed
using software available online. RPLP0 (Assay on Demand
Hs99999902_m1) and GAPDH (Hs99999905_m1) were analysed
in parallel as endogenous controls. All experiments included
several negative controls where cDNA were exchanged by water.
For each assay, the qRT-PCR reaction products were separated
by agarose gel electrophoresis to verify that a single product of the
expected size was amplified. Relative expression was calculated
using the DDCt method. Analysed samples had a Ct,35. Outliers
were automatically omitted from the analyses. Expression was
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samples and against GAPDH for non-parathyroid normal tissues.
The MCF-7 cell line was normalized against RPLP0 or GAPDH.
Relative quantification of gene expression was performed after
normalization in relation to an arbitrary expression level of 1.0
assigned to the MCF-7 cell line, or to the mean for normal
parathyroid samples. MCF-7 was chosen for comparison as it is
known to express high levels of PRLr according to a previous
publication by Peirce and Chen (42). All samples were run in
triplicates or quadruplicates from which mean values of expression
were calculated.
Reverse-Transcription PCR (RT-PCR)
Possible expression of the PRLR-DS1 transcript was determined
by RT-PCR using primers spanning selected exons followed by
visualization of products in agarose gels containing GelRed (Life
technologies, Delhi, India). Pooled cDNA samples from 4
parathyroid adenomas were used. cDNA (25 ng) was amplified
with 2 ml primer (IDT, Coralville, Iowa) at 100 mM and 2 ml MgCl
in 20 ml reactions under the conditions: 95uC for 10 min,
406[95uC for 30 sec, annealing at 55.5–70.3uC for 30 sec, 72uC
for 30 sec], and final 72uC. Primers for PRLR-DS1 were: Forward
in exons 3–6 (59-ATG TTC AGC CAG ACC CTC CT-39);
Reverse 1 in exon 7 (59-GCA AAA TGG ATC TCC CAC TC-
39); Reverse 2 in exon 6 (59-CTC CCA CTC AGC TGC TTT
CT-39); and Reverse 3 in exon 7 (59-AAA TGG ATC TCC CAC
TCA GC-39). Primer sequences for detection of the other PRLR
transcripts LF/DS1/S1a/S1b were: Forward in exon 3 (59-ACC
TGC CTT CTG AAT GGA C-39); Reverse 1 in exon 5 (59-TGT
ACT GCT TGC CAA AGT-39); Reverse 2 in exon 5 (59-GGC
CAC CGG TTA TGT AGT CT-39); and Reverse 3 in exon 5 (59-
CCA CCG GTT ATG TAG TCT GGA-39).
Antibodies
Details of the monoclonal antibodies used (clone, manufacturer
and working dilutions) are given in Table S1. The two PRLr
antibodies target the extra-cellular domain corresponding to exons
3–7 (anti-PRLrI, Invitrogen) and an intracellular epitope of exon
10 (anti-PRLrA, AnaSpec), respectively (Fig. S1). The gPRLr
antibody, specific for the N-glycosylated form of PRLr, targets the
extra-cellular domain of exons 3–7. Anti-GSK3b targets total
GSK3b, and the antibody for phosphorylated GSK3b is specific
for the serine 9 phosphorylated form of GSK3b only. For
fluorescent immunohistochemistry anti-GOLG1B and anti-
SCARB1 served as subcellular markers of Golgi and lysosomal
structures, respectively. Anti-GAPDH was used as a control of
protein loading and quality for Western blot analysis.
The PRLr antibodies were assessed for PRLr sensitivity by dot
blot analysis. Recombinant PRLr protein (0.1, 0.2 or 0.5 mg) for
amino acids (aa) 432–622 in the intracellular domain was
commercially obtained (Genway, San Diego, CA). The protein
was applied to a nitrocellulose membrane, blocked for 1 hour with
5% milk in TBS-T at room temperature, incubated with the
PRLrI or PRLrA antibodies, and developed as described for
Western blot analysis below. Positive signal was observed for
PRLrA, but not with PRLrI. No signal was observed with either
antibody in the negative control experiments.
The PRLrA antibody was further verified by immunprecipita-
tion. Dynabeads protein A (Invitrogen, Carlsbad, CA) were
incubated with 2 mg of PRLrI antibody for 30 minutes at room
temperature. 500 mg protein lysate from fallopian tube and
parathyroid tumour (to cover all isoforms) were incubated with
the antibody-bead-complex overnight under mild rotation at 4uC.
After resuspension in elution buffer, the beads were separated
using a magnet-rack. Immunoprecipitated samples were analysed
by Western blot using PRLrI or PRLrA antibodies, which both
revealed immunoreactivity against a 80 kDa product, correspond-
ing to the long isoform of PRLr.
Western Blot Analysis and Immunohistochemistry
Methodology for total protein extraction, Western blot analysis,
and immunohistochemistry has been previously described [56,57].
Immunohistochemistry was carried out on deparaffinized 4 mm
tissue slides. Working conditions were optimized for different heat
induced antigen retrieval techniques and antibody dilutions.
Antigen retrieval techniques included citrate- and EDTA-buffer
(heated 0, 10 and 20 minutes for each solution respectively), and
antibody dilution ranges were based on previous data and
recommended concentrations. For antigen retrieval, the slides
were treated with 95uC citrate buffer pH 6.0 (Dako, Glostrup,
Denmark) for 20 minutes in a microwave oven. Endogenous biotin
was neutralized using the Avidin-Biotin Blocking Kit (SP-2001,
Vector Laboratories, Burlingame, CA, USA). Slides were incu-
bated with a primary antibody (Table S1) diluted in 1% BSA at
4uC overnight followed by the horse anti-mouse biotinylated
secondary antibody diluted at 1:700 (BA-2000, Vector Laborato-
ries) for 45 minutes in room temperature, followed by Avidin-
biotin-peroxidase complex (Vectastain Elite Kit, Vector Labora-
tories, CA, USA) incubation for 45 minutes and diaminobenzidine
tetrahydrochloride for 6 minutes. Haematoxylin was used as
counterstaining. For negative controls, the primary antibody was
omitted. Negative controls were run in parallel to all experiments.
Slides were evaluated and photographed using a Zeiss Axioskop
(Carl Zeiss, Jena, Germany) equipped with Zeiss Plan-Neofluar
lenses, and a ProgRes C12 Plus camera, and ProgRes Capture Pro
2.5 software (Jenoptik, Jena, Germany). The immunostaining was
evaluated by four of the authors (F.H., C.J., C.L., A.H),
concerning expression and subcellular localisation, in tumour
and adjacent normal tissue if available. A subset of slides were
scanned in a slide scanner (Hamamatsu, Shizuoka, Japan) and
analyzed with NDP view software (Hamamatsu, Shizuoka, Japan).
Fluorescence Immunohistochemistry
Paraffin embedded tissue slides from three parathyroid adeno-
mas were analysed by fluorescence immunohistochemistry.
Primary antibodies: PRLrI, anti-SCARB2 (lysosymal marker)
and anti-GOLGB1 (Golgi marker) and fluorescent secondary
antibodies: Fluorescent anti-rabbit Alexa Fluor 488 (Abcam,
Cambridge, UK) and fluorescent anti-mouse Alexa Fluor 546
(Abcam, Cambridge, UK) were used for demonstrating the
presence and localization of the investigated proteins in tissue
sections, Images were obtained by Confocal Laser Scanning
Microscopy (CLSM), using a uniquely modified ConfoCor3
instrument (Carl Zeiss, Jena, Germany) consisting of an inverted
microscope for transmitted light and epifluorescence (Axiovert
200 M), a VIS-laser module comprising the Ar/ArKr (458, 477,
488 and 514 nm), HeNe 543 nm and HeNe 633 nm lasers and
the LSM 510 META module. The instrument was modified to
enable detection using silicon avalanche photodiodes (APD;
SPCM-AQR-1X, PerkinElmer, USA) for imaging. Triple fluores-
cence images were recorded using a standard HBO103 mercury
lamp for DAPI (blue pseudocolor), the 488 nm line of the Ar/
ArKr laser for Alexa Fluor 488 (green pseudocolor) and the
543 nm laser line for Alexa Fluor 546 (red pseudocolor). DAPI
fluorescence was acquired under bright field illumination and
point scan detection using a photomultiplier tube (PMT), whereas
Alexa Fluor 488 and 546 signals were acquired under confocal
setting using APD for signal detection. Fluorescent signals were
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and the BP 390-465 IR, BP 505-530 IR and LP 655 filters. The C-
Apochromat 406/1.2 W UV-VIS-IR objective was used through-
out. Images were recorded at 5126512 pixel resolution, without
averaging, scanning speed 25.6 ms/pixel.
Measurement of PTH Secretion by Perifusion
Perifusion analyses of PTH secretion were performed essentially
as previously described [55]. Cells were first suspended in medium
overnight to recover from collagenase digestion and analysed by
Trypan blue methodology to confirm high cell viability (.98%).
Cells (1610
4–1610
5) were subsequently loaded into a perifusion
column with P-4 gel, which was closed and kept at 37uC.
Perifusion was effectuated with a peristaltic pump at a speed of
500 ml/3 min. Before each experiment, preperifusion was done for
30 min with extracellular solution (EC), 1.5 mM Ca
2+ and basal
amino acid. Prolactin treatment included 9 min perifusion with
1.5 mM Ca
2+, addition of prolactin (recombinant
human prolactin, Cat. no JM-4687-50, MBL Woburn, MA) for
18 min, and washout. To verify cell viability after the experiment,
0.5 mM Ca
2+ was administered to the column. Samples were
collected every 3 min, stored at 220uC, and quantified for intact
PTH at the routine clinical chemistry laboratory in the Karolinska
University Hospital, Stockholm, Sweden (ISO 15189 certified). To
increase the comparability, effect of 100 mg/L and 200 mg/L
prolactin were tested in parallel using cells from the same
adenoma. Each protocol was performed four times with cells
from four different adenoma glands. To allow comparison, the
initial PTH level in each experiment was set to the arbitrary value
of 1, and the PTH levels were normalized accordingly.
Measurement of Intracellular Ca
2+ ([Ca
2+]i) by Fura-2
Measurements of [Ca
2+]i were carried out following procedures
previously described in detail by Lu et al. [55] In brief, isolated cells
were grown overnight on glass cover slips to enable attachment.
The cover slips were placed in a perifusion chamber at 37uC and
loaded with 2.5 mM Fura-2 AM (Invitrogen) in extracellular (EC)
perifusion solution supplemented with 1.25 mM CaCl2. The cells
were stepwise stimulated with 0.5 or 0.1 mM Ca
2+ and 1.5 mM
Ca
2+ followed by addition of prolactin at 100 or 200 mg/L.
Fluorescence was collected through an inverted fluorescence
microscope equipped with an 406 oil immersion objective, and
recorded using a cooled charged-coupled device (CCD) camera
connected with an imaging system. Fura-2 fluorescence was
alternately excited at 340 nm and 380 nm. In either case,
fluorescence emission at 505 nm was recorded. Fluorescence
intensities ratio F505
340=F505
380 was used to represent the [Ca
2+]i level.
Four independent experiments were performed on at least three
patient samples.
Expression Profiling
Expression profiling was done in parathyroid adenomas
subjected to prolactin treatment in culture. In addition, corre-
sponding paraffin sections were obtained for verification of PRLr
expression by immunohistochemistry. 200 mg/L prolactin (recom-
binant human prolactin, Cat. No. JM-4687-50, MBL Woburn,
MA) was added to 1610
6 attached parathyroid tumour cells. Cells
were harvested using RNAlater (QIAGEN) and homogenized with
QIAshredder for RNA extraction after 3 h and 24 h in culture,
respectively. Negative controls were collected in parallel with each
case at the same time points. RNA was extracted using QIA Cube,
and quality assessed with Bioanalyser and Nanodrop. Expression
array profiling and data analysis was done at the KI core facility
Bioinformatics and Expression Analysis (BEA, Novum, Huddinge)
using the Affymetrix platform and the TITAN ST 1.1 array. In
short; Ambion WT Expression kit was used for total RNA
conversion to sense strand cDNA, fragmentation and labelling
was accomplished with WT GeneChip WT target Labeling kit.
GeneTitan Hybridization, Wash and Stain Kit for WT Array
Plates were used for hybridization to Affymatrix Human Gene 1.1
ST Array Plates. Plates were scanned using Affymatrix GeneChip
HT Array Plate Scanner. Pre-processing of data was conducted
with the Affymatrix Expression Console using the following
methods: Summarization: PLIER, Background: Correction: PM-
GC-BG, Normalization: Global Median. Value definition: Un-
transformed signals. A total of 16 samples were analysed including
4 parathyroid adenomas cultured for 3 h or 24 h in the presence of
prolactin plus control samples cultured in parallel without
prolactin.
Post process data analyses were performed as follows. After
normalization, probe sets with mean expression values below 30 in
both treated and untreated sample groups were excluded. In order
to detect both early and late genes, samples were grouped into
treated (n=8) and untreated (n=8) cells. Paired t-test was
performed for comparative analysis to exclude non-significant
genes. Individual gene inclusion criteria included; P-value of
,0.01 and fold change of ,2 1.4 or .1.4. Filtered genes were
analysed by WebGestalt (http://bioinfo.vanderbilt.edu/
webgestalt/option.php) for enrichment analysis (KEGG and
Wikipathways by hypergeometric distribution, cut-offs included a
minimal significance level of P,0.02 and minimum 4 genes) and
gene ontology (GO) classification. All microarray data are
available at NCBI’s Gene Expression Omnibus, and are available
through accession number GSE32387, or http://www.ncbi.nlm.
nih.gov/sites/GDSbrowser?acc=GDS32387. For PCA plot and
Heatmap generation, pre-processed data was analysed in Qlucore
(Qlucore AB, Lund Sweden). Data were corrected nominally for
individual dependency with an additional variance filtering of 7e-
4. We employed a two-group comparison, two sided t-test with a
adjusted P-value cut-off of ,0.01.
Statistical Analyses
All statistical calculations of clinical data were performed using
the IBM SPSS software (Statistical Software Package for Windows,
V.20). Data was analysed with the Pearson Chi-Square test for
qualitative variables and Mann-Whitney U test for continuous
variables. Relationships between variables were assessed with
Spearman’s rank correlation test. P-values ,0.05 were taken as
statistically significant.
Supporting Information
Figure S1 Schematic illustration of the mRNA tran-
scripts and corresponding protein isoforms for the
prolactin receptor gene locus. Location of qRT-PCR assays
are indicated at the top, approximate protein sizes to the left and
location of antibody epitopes and GSK3b interaction site below.
LF=Long form, DS1=delta S1, IF=intermediate form,
S1a=short form 1a, S1b=short form 1b.
(TIF)
Figure S2 Results from qRT-PCR analysis of the PRLR
gene in individual samples of normal tissues as com-
pared to the MCF-7 cell-line. The column charts show results
from the assays PRLR-total (for LF, DS1, IF and S1a), PRLR-LF1
(for LF and DS1), PRLR-LF2 (for LF and DS1) (A); and the assay
PRLR-S1a for the S1a transcript only (B). The arbitrary expression
level of 1.0 indicates the expression level for MCF-7 cells.
(TIF)
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gene in individual samples of parathyroid tumours and
normal parathyroids. The column charts show results from
the assays PRLR-total (for LF, DS1, IF and S1a), PRLR-LF1 (for LF
and DS1), PRLR-LF2 (for LF and DS1), and PRLR-S1a (for S1a).
The arbitrary expression level of 1.0 indicates the mean expression
value for normal parathyroids.
(TIF)
Figure S4 Immunohistochemical analysis of PRLr ex-
pression in normal rim and three different parathyroid
tumours using the PRLrA antibody. A) In normal rim
immunoreactivity is observed in cytoplasm and/or plasma
membrane. In the tumours PRLr expression is localized in plasma
membrane and cytoplasm (B), in cytoplasm (C), and in plasma
membrane and cytoplasm (D).
(TIF)
Table S1 Details of antibodies used in this study.
(XLS)
Table S2 Differentially expressed probe sets/genes in
prolactin treated vs. untreated parathyroid tumors.
(XLS)
Table S3 Gene expression and subcellular localization
of the prolactin receptor in parathyroid tumor panel.
(XLS)
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